Should I Buy BRKR? BRKR 2026 Analysis

Should You Buy Bruker Corp (BRKR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

41.930

1 Day change

2.17%

52 Week Range

56.480

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price is breaking below key support (S1 ~43.35) with downside momentum still building (MACD histogram negative and expanding).
While the stock is extremely oversold (RSI_6 ~~16) and could bounce near S2 (~~40.69), the current tape favors further weakness before a durable reversal.
Options positioning is mildly bullish (put/call ratios < 1), but there is no Intellectia buy signal (AI Stock Picker/SwingMax) to override the bearish trend.
Upcoming earnings (2026-02-12 pre-market) is the next major catalyst; without positive pre-announcements/news, buying now is more of a gamble than an edge.

Technical Analysis

Trend/Momentum: Bearish. MACD histogram = -1.054 (below 0) and negatively expanding → selling pressure increasing.
RSI: RSI_6 = 16.19 → deeply oversold, raising odds of a short-term relief bounce, but oversold can persist in downtrends.
Moving averages: Converging MAs suggests compression, but current momentum is still down.
Key levels: Pivot 47.65 (well above price). Pre-market ~42.01 is below S1 43.35 and approaching S2 40.69; resistance overhead at 47.65 then 51.95.
Pattern-based expectation: Similar-pattern model implies modest near-term upside (next day/week) but negative 1-month bias (-5.04%).

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Skews mildly bullish (more call participation vs puts) based on both OI and volume put/call ratios below 1.
Volatility: IV (30d) ~55.47 vs HV ~39.74 → options pricing implies elevated expected moves vs realized; can reflect uncertainty into earnings.
Activity: Today’s volume (444) is ~~34.71% of 30D average (not a spike), while open interest is elevated vs its 30D average (~~104.75%) → positioning exists but not a fresh sentiment surge.

Technical Summary

Sell

Buy

Positive Catalysts

pointing to a 2026 recovery/margin expansion story.
- proximity to S2 (~40.
can fuel a quick mean-reversion bounce.

Neutral/Negative Catalysts

with MACD downside expansion increases probability of another leg down.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $860.5M, down -0.45% YoY (flat-to-down top line).
Profitability: Net income -$62.4M (down -252.57% YoY) and EPS -$0.41 (down -251.85% YoY) → sharp deterioration.
Margins: Gross margin 46.44%, down -4.42% YoY → pressure on operating leverage.
Takeaway: Financial trend is currently negative; the bull case depends on a 2026 recovery that has not yet shown up in these numbers.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend: Strongly improving since mid-Dec 2025—numerous firms raised price targets (e.g., BofA to $60, JPM to $55, Barclays/Wells to $55, TD Cowen to $53, Citi to $53, Guggenheim up to $58) and Wolfe upgraded to Outperform with a $60 PT.
Pros (Wall St. bull view): 2026 recovery setup in life science tools, expected margin expansion, improved visibility/backlog (per Wolfe), and valuation upside if growth re-accelerates.
Cons (Wall St. cautious view): Some still hold Neutral/Hold (Citi Neutral, TD Cowen Hold), implying execution/market-recovery timing risk; recent weak quarter supports caution.
Influential/political trading: No recent congress trading data available; insider/hedge fund trend signals are neutral.

12 Analyst Rating

Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

4 Hold

1 Sell

Moderate Buy

Current: 41.040

Low

Averages

52.18

High

Current: 41.040

Low

Averages

52.18

High

Guggenheim

Buy

maintain

$53 -> $58

AI Analysis

2026-01-26

Reason

Guggenheim

Price Target

$53 -> $58

AI Analysis

2026-01-26

maintain

Buy

Reason

Guggenheim raised the firm's price target on Bruker to $58 from $53 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

Citi

Neutral

maintain

$40 -> $53

2026-01-16

Reason

Citi

Price Target

$40 -> $53

2026-01-16

maintain

Neutral

Reason

Citi raised the firm's price target on Bruker to $53 from $40 and keeps a Neutral rating on the shares. The firm adjusted targets in the life science tools and diagnostics group after meeting with companies. Commentary around pharma was positive, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BRKR

Unlock Now

BRKR Should I Buy

BRKR Should I Buy

Should You Buy Bruker Corp (BRKR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch